Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WBC100 in Relapsed or Refractory Acute Myeloid Leukemia
NCT07014449Phase 1Recruiting
- Sponsor
- Weben Pharma
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of WBC100 in acute myeloid leukemia (AML) (2 cohorts), sponsored by Weben Pharma. Primary endpoints: Dose-Limiting Toxicities at 28 days, Treatment-Emergent Adverse Events and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
WBC100
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07014449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07014449.